The UK government-backed fund has secured commitments from Biogen, GlaxoSmithKline, Johnson & Johnson, Lilly, Pfizer and Takeda.

Pharco Pharamceuticals led Naia's series A round, which will support the development of drugs including an orphan treatment for SBS.

The connected healthcare IT provider has closed a Qualcomm-led series B round that increased its overall funding to $17m.

Phaarmaceutical company Humacyte has raised $150m in an Access Industries-backed series B round that will fund phase 3 trials for its renal disease technology.

Conrad Wang has left Medtronic, where he oversaw corporate venturing investments and acquisitions, to join investment firm Healthcare Royalty Partners.

China-based immuno-oncology company BeiGene, which has raised more than $170m in the past year, will advance four of its drug candidates with the proceeds.

3M has led the first tranche of the drug delivery technology company's $12m series B round, closed in conjunction with the formation of an alliance with 3M Drug Delivery Systems.

The surgical imaging technology developer closed a $9m round today that was co-led by HTC, the producer of a virtual reality headset compatible with the technology.

Fosun's pharmaceutical wing invested $20m in the diagnostic testing technology company as part of a strategic partnership, boosting its overall equity funding to $115m.